JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary

JMA Executive Board Member Kichiro Matsumoto Now that Japan has decided to introduce a cost-effectiveness assessment (CEA) system in April 2019, we are interviewing key stakeholders and policymakers about their views on the government’s proposal and challenges it might face...read more